Nektar Therapeutics (ETR:ITH0)
Germany · Delayed Price · Currency is EUR | Market Cap | 2.16B +392.5% |
| Revenue (ttm) | 47.78M -27.2% |
| Net Income | -137.53M |
| EPS | -5.66 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26 |
| Open | 64.28 |
| Previous Close | 62.94 |
| Day's Range | 64.28 - 64.28 |
| 52-Week Range | 47.97 - 66.72 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has col... [Read more]
Financial Performance
In 2025, Nektar Therapeutics's revenue was $55.23 million, a decrease of -43.89% compared to the previous year's $98.43 million. Losses were -$164.08 million, 37.9% more than in 2024.
Financial numbers in USD Financial StatementsNews
Nektar reinstated with a Neutral at JPMorgan
JPMorgan analyst Jessica Fye reinstated coverage of Nektar (NKTR) with a Neutral rating and $65 price target The company is entering a “trial execution phase for rezpeg” with a “replenished”…
Nektar reports Q2 EPS ($1.23), consensus ($2.04)
Reports Q2 revenue $10.1M, consensus $10.47M. “This year continues to be a transformative year for Nektar (NKTR) as we advance our lead program, rezpegaldesleukin, into Phase 3 clinical trials,” said…
Nektar Therapeutics Earnings Call Transcript: Q2 2026
Phase III programs for REZPEG in atopic dermatitis and alopecia areata are advancing, supported by strong cash reserves and positive physician feedback on efficacy, safety, and dosing. Top-line phase III data are expected in 2028, with BLA submission planned for 2029.
Nektar Therapeutics Earnings release: Q2 2026
Nektar Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Nektar Therapeutics Quarterly report: Q2 2026
Nektar Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Nektar Therapeutics Announces Second Quarter 2026 Financial Results
SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial r...
Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, July 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026, after the c...
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, July 24, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on July 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors grant...
Nektar initiated with a Buy at Canaccord on rezpegaldesleukin potential
As previously reported, Canaccord analyst Edward Nash initiated coverage of Nektar (NKTR) with a Buy rating and $153 price target The Phase 3 program for lead asset rezpegaldesleukin in atopic…
Nektar initiated with a Buy at Canaccord
Canaccord analyst Edward Nash initiated coverage of Nektar (NKTR) with a Buy rating and $153 price target
Nektar begins Phase 3 program of rezpegaldesleukin in atopic dermatitis
Nektar (NKTR) announced the initiation of the first two global registrational trials in the Phase 3 ZENITH AD program for rezpegaldesleukin. The ZENITH AD program is evaluating rezpegaldesleukin in pa...
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Two global registrational Phase 3 trials initiated in ZENITH AD program Phase 3 program based upon clinically meaningful efficacy and favorable safety data observed in 393-patient Phase 2b study with ...
Nektar Therapeutics Transcript: AGM 2026
The meeting approved all four proposals, including director election and plan amendments. Immunology pipeline advances with REZPEG moving to phase III, and strong cash reserves support future studies. Collaboration on REZPEG is possible, but licensing is not planned.
Nektar Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Rezpegaldesleukin, a Treg agonist, is advancing through global phase III trials for atopic dermatitis, with robust design and strategic differentiation for biologic-naive and experienced populations. Additional studies in alopecia and type 1 diabetes are planned, with broad potential across immune-mediated diseases.
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global Healthcare Conf...
Nektar price target lowered to $80 from $95 at Wedbush
Wedbush analyst Martin Fan lowered the firm’s price target on Nektar (NKTR) to $80 from $95 and keeps a Neutral rating on the shares. The firm notes the company reported…
Nektar price target raised to $192 from $105 at Piper Sandler
Piper Sandler analyst Yasmeen Rahimi raised the firm’s price target on Nektar (NKTR) to $192 from $105 and keeps an Overweight rating on the shares. The firm notes the company…
Nektar Therapeutics Earnings Call Transcript: Q1 2026
REZPEG advanced with strong phase IIb data in atopic dermatitis and alopecia areata, supporting phase III trials and a BLA submission by 2029. Over $1 billion in cash ensures funding through key milestones, with a robust pipeline and favorable market outlook.
Nektar Therapeutics Earnings release: Q1 2026
Nektar Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Nektar Therapeutics Quarterly report: Q1 2026
Nektar Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Nektar reports Q1 adjusted EPS ($1.82), consensus ($1.48)
Reports Q1 revenue $10.86M, consensus $10.69M. “2026 is shaping up to be a defining year for Nektar (NKTR) and for our lead biologic candidate rezpegaldesleukin,” said Howard Robin, President and…
Nektar Therapeutics Reports First Quarter 2026 Financial Results
SAN FRANCISCO, May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2026. Cash and investments in marketable securities...
Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, April 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 7, 2026, after the close of U.S.-based finan...
Nektar Therapeutics Proxy statement: Proxy filing
Nektar Therapeutics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Nektar Therapeutics Proxy statement: Proxy filing
Nektar Therapeutics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.